¼¼°èÀÇ ÀÓ»ó Áø´Ü »óÀ§ 6´ë ¼ºÀå ±âȸ(2025³â)
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
»óǰÄÚµå : 1630571
¸®¼­Ä¡»ç : Frost & Sullivan
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 13 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,450 £Ü 3,459,000
Web Access (Regional License) help
Frost & SullivanÀÇ À¥»çÀÌÆ® ·Î±×ÀÎ ÆÐ½º¿öµå°¡ ¹ßÇàµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµÉ ¿¹Á¤ÀÔ´Ï´Ù. PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


Çѱ۸ñÂ÷

»õ·Î¿î °Ë»ç ½ÂÀÎ ¹× °Ë»ç ÀÚµ¿È­ ¼Ö·ç¼ÇÀÌ Çõ½ÅÀû ¼ºÀåÀ» ÁÖµµ

Àüü ÀÇ·áºñÀÇ 2-3%¸¦ Â÷ÁöÇϰí ÀÓ»ó ÀÇ»ç°áÁ¤ÀÇ 70%¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áø´ÜÇÐÀº À§Çè ºÐ·ù, ½ºÅ©¸®´×, Á¶±â Áø´Ü, ¿¹ÈÄ, ¸ð´ÏÅ͸µ, Àç¹ß µî Á¤¹ÐÀÇ·áÀÇ ¸ðµç ´Ü°è¸¦ µÞ¹ÞħÇÏ´Â Á¶¿ëÇÑ Ã¨ÇǾðÀÔ´Ï´Ù.

Ç÷¾× ±â¹Ý ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß°ß ¹× º¯È¯, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹Þ±â À§ÇÑ ¾à¹° Áø´Ü Á¶ÇÕÀÇ Áö¼ÓÀûÀÎ ¼ºÀå, ½Å¼ÓÇÑ Ç×±ÕÁ¦ ³»¼º Áø´ÜÀÇ °íÀ¯ÇÑ ±âȸ´Â Ä¡·á °áÁ¤À» °³¼±Çϰí Á¤¹Ð ÀÇ·á °æ·Î¸¦ Çõ½ÅÇϱâ À§ÇØ Áø´Ü ¾ÖÇø®ÄÉÀ̼ǿ¡ ³»ÀåµÈ ÀûÀÀ¼ºÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ¶ÇÇÑ º´¸®ÇÐ Àη ºÎÁ·, Á¤È®¼º¿¡ ´ëÇÑ ¿ì·Á, °¡°Ý ¹× ÀÚ¿øÀÇ ºÒ±ÕµîÇÑ ºÐ¹è µî ÀÌ ºÐ¾ß°¡ Á÷¸éÇÑ Áö¼ÓÀûÀÎ °úÁ¦¸¦ °í·ÁÇÒ ¶§, Ŭ¶ó¿ìµå ±â¹Ý ¼Ö·ç¼Ç, ¿ø°Ý ¾×¼¼½º ¹× ½Ç½Ã°£ µ¥ÀÌÅÍ ¸ð´ÏÅ͸µÀº Àü·Ê ¾ø´Â ÁøÈ­¸¦ °ÅµìÇϰí ÀÖÀ¸¸ç, Àü ¼¼°è ¾÷¹«¸¦ À籸¼ºÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ ºÐ¾ß°¡ Ä¡·á ¹æÄ§ °áÁ¤°ú Á¤¹Ð °æ·ÎÀÇ º¯È­¸¦ ÇâÇØ ±Þº¯ÇÏ´Â °¡¿îµ¥, ±â¼ú ¹ßÀü, ½ÃÀå ¿ä±¸, ȯÀÚ ±â´ëÀÇ »ïÀ§ÀÏü·Î ÀÎÇØ Àü ¼¼°è Áø´Ü »ýŰ谡 º¯È­Çϰí ÀÖ½À´Ï´Ù. Á¦Ç° ¹× ¼­ºñ½ºÀÇ °¡°Ý ÀÎÇÏ, ÀÚº» ÁöÃâ °¨¼Ò, »çÀ̹ö º¸¾È °­È­¸¦ À§ÇÑ ÀÚ±Ý È®º¸°¡ ¿ä±¸µÇ°í ÀÖÀ¸¸ç, Áø´ÜÀÇ È¿À²¼º Çâ»ó¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌÇØ°ü°èÀڵ鿡°Ô Áß¿äÇÑ °ÍÀº ´ë½Ãº¸µå¿Í ½Ç½Ã°£ ºÐ¼®À» ÅëÇØ Á¦Ç°ÀÇ Á¤º¸±â¼ú(IT) ±¸¼º¿ä¼Ò¸¦ ¾÷±×·¹À̵åÇϰí, Á¤¹ÐÇÑ Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â ÅëÇÕÀûÀ̰í È®Àå °¡´ÉÇÑ µ¥ÀÌÅͺ£À̽º ±â¹ÝÀÇ Áø´Ü ¸ðµ¨¿¡ ´ëÇÑ ¼ö¿ä¸¦ ºÒ·¯ÀÏÀ¸Å°´Â °ÍÀÔ´Ï´Ù.

¸ñÂ÷

2025³â »óÀ§ ¼ºÀå ±âȸ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Approval of New Tests and Laboratory Automation Solutions are Driving Transformational Growth

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse.

The discovery and translation of blood-based neurology biomarkers, sustained growth in drug-diagnostic combinations seeking regulatory approval, and unique opportunities in rapid antimicrobial resistance diagnostics necessitate built-in adaptability in diagnostics applications to improve therapeutic decisions and transform precision healthcare pathways. Moreover, given the persistent challenges the sector is facing, including the pathology workforce shortage, accuracy concerns, and uneven distribution of prices and resources, cloud-based solutions, remote access, and real-time data monitoring are evolving unprecedentedly and promising to reshape operations globally.

As the sector undergoes a seismic shift to improve therapeutic decisions and transform precision pathways, the trifecta of technological advancements, market demands, and patient expectations is transforming the global diagnostics ecosystem. The need to make products and services more affordable, reduce capital expenditure, and free up funds to improve cybersecurity will forge demand for greater diagnostics efficiency. The key for stakeholders will be to upgrade products' information technology (IT) components through dashboards and real-time analytics and forge demand for a unified, scalable data-based diagnostic model capable of delivering precision care.

Table of Contents

Top Growth Opportunities for 2025

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â